Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes in Body Composition After EPA Supplementation in Head and Neck Patients (hepaneck)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02715596
Recruitment Status : Completed
First Posted : March 22, 2016
Last Update Posted : September 4, 2019
Sponsor:
Collaborator:
Ferrer Internacional S.A.
Information provided by (Responsible Party):
Institut Català d'Oncologia

Brief Summary:
Evaluates the effect of EPA supplementation in terms of muscle mass in patients with squamous cell carcinoma of the head and neck locally advanced

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of Head and Neck Dietary Supplement: EPA supplementation Other: Placebo Phase 3

Detailed Description:
This study is designed to evaluate the effect of EPA supplementation on muscle mass in patients with squamous cell carcinoma of the head and neck locally advanced (stage III-IVb) to assess that supplementation with EPA can maintain muscle mass along the oncologic treatment. Other aims are to evaluate the nutritional status, acute and chronic toxicities related with the loss of muscle mass and the impact of the EPA supplementation on overall and disease-free survival.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: eicosapentanoic acid (EPA) versus placebo
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Placebo (EPA)
Primary Purpose: Supportive Care
Official Title: Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb)
Actual Study Start Date : December 23, 2015
Actual Primary Completion Date : March 1, 2019
Actual Study Completion Date : September 2, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention A
2.7 g EPA supplementation in a 15 cc emulsion stick-pack
Dietary Supplement: EPA supplementation
2.7 g EPA supplementation in a 15 cc emulsion stick-pack

Placebo Comparator: Intervention B
Placebo supplementation in a 15 cc emulsion stick-pack
Other: Placebo
placebo in 15 cc emulsion stick-pack




Primary Outcome Measures :
  1. The effect of supplementation with EPA on muscle mass during a conservative non-surgical treatment of organ in patients with squamous cell carcinoma of head and neck locally advanced. [ Time Frame: 3 years ]
    To evaluate the effect of supplementation with EPA on muscle mass during a conservative non-surgical treatment of organ in patients with squamous cell carcinoma of head and neck locally advanced.


Secondary Outcome Measures :
  1. the effect of supplementation with EPA on muscle mass after induction chemotherapy using imaging such as CT scan [ Time Frame: 10 weeks ]
    To evaluate on muscle mass using imaging such as CT scan

  2. Evolution of nutritional status of patients over oncology-specific treatment in both arms. using PG-VGS [ Time Frame: 1 year ]
    To assess the evolution of nutritional status using PG-VGS (patient generated subjective global assessment)

  3. The effect of supplementation with EPA regarding acute toxicity during treatment.using the CTCAE v4 criteria [ Time Frame: 1 year ]
    To evaluate the frequency of acute toxicity using the CTCAE v4 criteria

  4. The effect of supplementation with EPA in relation to chronic toxicity 2 years after oncologic treatment. (using the CTCAE v4 criteria) [ Time Frame: 2 years ]
    To evaluate the frequency of chronic toxicity using the CTCAE v4 criteria

  5. The impact of supplementation with EPA in the loco-regional control at 2 years after completing cancer treatment. [ Time Frame: 2 years ]
    To evaluate whether the effect of supplementation with EPA influences the loco-regional control using a CT scan

  6. The effect of supplementation with EPA on the perceptions of patients through quality of life validated questionnaires. [ Time Frame: 2 year ]
    o To evaluate and compare the effect of supplementation with EPA on the perceptions of patients through quality of life questionnaires (QLQ) validated such as QLA-C30

  7. The adherence to EPA. (using record EPA/placebo dispensing and return and blood samples at baseline and throughout the cancer treatment) [ Time Frame: 1 year ]
    To assess adherence to EPA using record EPA/placebo dispensing and return and blood samples at baseline and throughout the cancer treatment of the EPA concentration in the erythrocyte membrane

  8. The functional status of patients throughout the treatment. (functional status using hand grip) [ Time Frame: 1 year ]
    To evaluate the functional status using hand grip

  9. The need for nutritional support and nutritional intervention required during cancer treatment among patients supplemented with EPA or placebo. [ Time Frame: 1 year ]
    To compare the need for nutritional support and nutritional intervention required using data collection sheet with the different types of nutritional support, days of each nutritional intervention and adherence to it.

  10. The impact of supplementation with EPA on the recurrence-free survival at 2 years after completing cancer treatment. [ Time Frame: 2 years ]
    To evaluate whether the effect of supplementation with EPA influences the recurrence-free survival using a CT scan

  11. The impact of supplementation with EPA on the overall survival at 2 years after completing cancer treatment. [ Time Frame: 2 years ]
    To evaluate whether the effect of supplementation with EPA influences the overall survival using a CT scan

  12. The effect of supplementation with EPA on the perceptions of patients through quality of life validated questionnaires. [ Time Frame: 2 years ]
    To evaluate and compare the effect of supplementation with EPA on the perceptions of patients through quality of life questionnaires (QLQ) validated such as QLQ-H&N35

  13. The functional status of patients throughout the treatment. (functional status using performance status scale) [ Time Frame: 1 year ]
    To evaluate the functional status using performance status scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • - Age between 18 and 75 years inclusive.
  • A performance status 0-1 according to ECOG (Eastern Cooperative Oncology Group) scale at the time of inclusion in the study.
  • Expectancy greater than 3 months life.
  • Location: oral cavity, oropharynx, larynx,hypopharynx, nasopharynx and sinuses.
  • Patients with squamous cell carcinoma of the head and neck classified as locally advanced (Stage III, IVa-IVb).
  • Patients with medical conditions to receive neoadjuvant chemotherapy (CT) induction followed by radiotherapy (RDT) normo fraction combined with QT or biological.
  • Neutrophil ≥1500 / mm3, platelet count ≥150,000 / mm3 and hemoglobin ≥10g / dL.
  • Adequate liver function: total bilirubin ≤ 1 x ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; Alkaline phosphatase (ALP) ≤ 5 x ULN.
  • Serum albumin-adjusted calcium ≤ 1.25 x upper limit of normal (ULN).
  • Using an effective contraceptive method for patients of both sexes where the risk of conception and / or pregnancy.
  • Signature of written informed consent before any study-specific procedures

Exclusion Criteria:

  • - Metastatic disease (stage IVc).
  • Surgery, radiotherapy and / or chemotherapy prior to study disease treatment.
  • T3 N0-1 larynx.
  • Other stadiums than III or IV without distant metastases and stable disease.
  • Another synchronous squamous carcinoma.
  • Diagnosis of other malignancy within the past 5 years, except in situ of the cervix and / or adequately treated basal cell carcinoma skin cancer.
  • Active infection (infection requiring intravenous antibiotic), including active tuberculosis and HIV diagnosed.
  • Uncontrolled hypertension defined as systolic blood pressure ≥180mm Hg and / or diastolic blood pressure≥ 130 mm Hg at rest.
  • Pregnancy (absence must be confirmed with β-HCG (Human chorionic gonadotropin) serum test) or lactating.
  • Systemic, chronic immune and concomitant treatment, or hormonal treatment of cancer.
  • Other concomitant antineoplastic treatment.
  • Clinically significant coronary artery or a history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled heart failure.
  • Chronic obstructive pulmonary disease that would have required ≥3 hospitalizations in the last 12 months.
  • Uncontrolled active peptic ulcer.
  • Presence of a psychological or medical illness that prevented the study by the patient or to grant the signature on the informed consent.
  • Abuse of known drugs (with the exception of heavy drinking).
  • Allergic reaction known against any component of study treatment.
  • Previous treatment with monoclonal antibodies or other inhibitors of signal transduction or treatment directed against the EGFR (epidermal growth factor receptor).
  • Any experimental therapy within 30 days prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715596


Locations
Layout table for location information
Spain
Institut Catala d'Oncologia- L'Hospitalet
L´hospitalet de Llobregat, Barcelona, Spain, 08908
Sponsors and Collaborators
Institut Català d'Oncologia
Ferrer Internacional S.A.
Investigators
Layout table for investigator information
Principal Investigator: Lorena Arribas, RD, MsC Institut Català d'Oncologia
Layout table for additonal information
Responsible Party: Institut Català d'Oncologia
ClinicalTrials.gov Identifier: NCT02715596    
Other Study ID Numbers: PR 261/14
First Posted: March 22, 2016    Key Record Dates
Last Update Posted: September 4, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Institut Català d'Oncologia:
head and neck
eicosapentanoic acid
body composition
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site